975 Shares in Cencora, Inc. $COR Purchased by Retireful LLC

Key Points

• Retireful LLC acquired 975 shares of Cencora, Inc. for approximately $292,000, highlighting increasing interest from institutional investors as they currently own 97.52% of the stock.
• CEO Robert P. Mauch and Chairman Steven H. Collis executed significant stock sales, resulting in an 11.49% and 9.30% decrease in their respective ownership stakes.
• Analysts have a consensus "Moderate Buy" rating for Cencora, with a target price raised to $354.00 by Wells Fargo, amid a recent stock performance that includes a 2.0% increase on the trading day.

Retireful LLC acquired a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 975 shares of the company's stock, valued at approximately $292,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Net Worth Advisory Group boosted its holdings in shares of Cencora by 1.4% in the first quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock valued at $736,000 after purchasing an additional 36 shares during the period. Obermeyer Wealth Partners lifted its holdings in shares of Cencora by 1.3% in the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company's stock worth $758,000 after buying an additional 36 shares during the period. Grove Bank & Trust grew its position in shares of Cencora by 4.3% during the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company's stock worth $264,000 after buying an additional 36 shares in the last quarter. U.S. Capital Wealth Advisors LLC increased its stake in shares of Cencora by 0.4% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company's stock valued at $2,563,000 after buying an additional 38 shares during the period. Finally, Cromwell Holdings LLC raised its holdings in shares of Cencora by 9.5% in the first quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock valued at $125,000 after acquiring an additional 39 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Cencora

In other news, CEO Robert P. Mauch sold 5,097 shares of the business's stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the completion of the sale, the chief executive officer owned 39,274 shares of the company's stock, valued at $11,389,460. The trade was a 11.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven H. Collis sold 31,350 shares of the firm's stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 55,993 shares of company stock valued at $16,292,923. 10.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have commented on COR. Wells Fargo & Company raised their target price on shares of Cencora from $337.00 to $354.00 and gave the company an "overweight" rating in a research report on Wednesday, August 13th. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the company an "equal weight" rating in a report on Wednesday, July 16th. Finally, Jefferies Financial Group upped their target price on Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a report on Monday, June 30th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, Cencora currently has a consensus rating of "Moderate Buy" and an average target price of $311.25.

Cencora Stock Up 2.0%

Cencora stock opened at $308.33 on Thursday. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The firm has a market cap of $59.78 billion, a price-to-earnings ratio of 31.72, a price-to-earnings-growth ratio of 1.54 and a beta of 0.62. The business's 50-day moving average price is $292.62 and its 200 day moving average price is $287.78. Cencora, Inc. has a 52 week low of $218.65 and a 52 week high of $309.64.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.21. The firm had revenue of $80.66 billion during the quarter, compared to analyst estimates of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.Cencora's revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.34 EPS. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.7%. Cencora's dividend payout ratio (DPR) is currently 22.63%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.